메뉴 건너뛰기




Volumn 13, Issue 1, 2014, Pages 11-14

Targets for new immunomodulation strategies in inflammatory bowel disease

Author keywords

Cytokine blockers; Inflammatory bowel diseases; Smad7; Therapeutic targets

Indexed keywords

CHEMOKINE RECEPTOR CCR9; FONTOLIZUMAB; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 18; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 26; OSTEOPONTIN; STAT4 PROTEIN; THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA1; VERCIRNON;

EID: 84886951355     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.003     Document Type: Review
Times cited : (35)

References (70)
  • 1
    • 70949107842 scopus 로고    scopus 로고
    • Inflammatory bowel disease
    • Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
    • (2009) N Engl J Med , vol.361 , pp. 2066-2078
    • Abraham, C.1    Cho, J.H.2
  • 3
    • 34547176642 scopus 로고    scopus 로고
    • Unravelling the pathogenesis of inflammatory bowel disease
    • Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
    • (2007) Nature , vol.448 , pp. 427-434
    • Xavier, R.J.1    Podolsky, D.K.2
  • 4
    • 33847381116 scopus 로고    scopus 로고
    • The fundamental basis of inflammatory bowel disease
    • Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
    • (2007) J Clin Invest , vol.117 , pp. 514-521
    • Strober, W.1    Fuss, I.2    Mannon, P.3
  • 6
    • 0030209985 scopus 로고    scopus 로고
    • Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5
    • Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996, 157:1261-1270.
    • (1996) J Immunol , vol.157 , pp. 1261-1270
    • Fuss, I.J.1    Neurath, M.2    Boirivant, M.3    Klein, J.S.4    de la Motte, C.5    Strong, S.A.6
  • 8
    • 0035314015 scopus 로고    scopus 로고
    • Stability and commitment in T helper cell development
    • Asnagli H., Murphy K.M. Stability and commitment in T helper cell development. Curr Opin Immunol 2001, 13:242-247.
    • (2001) Curr Opin Immunol , vol.13 , pp. 242-247
    • Asnagli, H.1    Murphy, K.M.2
  • 9
    • 0030995575 scopus 로고    scopus 로고
    • Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
    • Monteleone G., Biancone L., Marasco R., Morrone G., Marasco O., Luzza F., et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997, 112:1169-1178.
    • (1997) Gastroenterology , vol.112 , pp. 1169-1178
    • Monteleone, G.1    Biancone, L.2    Marasco, R.3    Morrone, G.4    Marasco, O.5    Luzza, F.6
  • 10
    • 23944521291 scopus 로고    scopus 로고
    • Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease
    • Gordon J.N., MacDonald T.T. Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease. Gut 2005, 54:1213-1215.
    • (2005) Gut , vol.54 , pp. 1213-1215
    • Gordon, J.N.1    MacDonald, T.T.2
  • 12
    • 0034176003 scopus 로고    scopus 로고
    • IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production
    • Liu Z., Geboes K., Colpaert S., D'Haens G.R., Rutgeerts P., Ceuppens J.L. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol 2000, 164:3608-3615.
    • (2000) J Immunol , vol.164 , pp. 3608-3615
    • Liu, Z.1    Geboes, K.2    Colpaert, S.3    D'Haens, G.R.4    Rutgeerts, P.5    Ceuppens, J.L.6
  • 13
    • 0028861975 scopus 로고
    • Antibodies to interleukin 12 abrogate established experimental colitis in mice
    • Neurath M.F., Fuss I., Kelsall B.L., Stuber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995, 182:1281-1290.
    • (1995) J Exp Med , vol.182 , pp. 1281-1290
    • Neurath, M.F.1    Fuss, I.2    Kelsall, B.L.3    Stuber, E.4    Strober, W.5
  • 14
    • 0033558364 scopus 로고    scopus 로고
    • Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens
    • Wirtz S., Finotto S., Kanzler S., Lohse A.W., Blessing M., Lehr H.A., et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. J Immunol 1999, 162:1884-1888.
    • (1999) J Immunol , vol.162 , pp. 1884-1888
    • Wirtz, S.1    Finotto, S.2    Kanzler, S.3    Lohse, A.W.4    Blessing, M.5    Lehr, H.A.6
  • 15
    • 0032530697 scopus 로고    scopus 로고
    • IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice
    • Davidson N.J., Hudak S.A., Lesley R.E., Menon S., Leach M.W., Rennick D.M. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998, 161:3143-3149.
    • (1998) J Immunol , vol.161 , pp. 3143-3149
    • Davidson, N.J.1    Hudak, S.A.2    Lesley, R.E.3    Menon, S.4    Leach, M.W.5    Rennick, D.M.6
  • 16
    • 33746176176 scopus 로고    scopus 로고
    • Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
    • Hommes D.W., Mikhajlova T.L., Stoinov S., Stimac D., Vucelic B., Lonovics J., et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006, 55:1131-1137.
    • (2006) Gut , vol.55 , pp. 1131-1137
    • Hommes, D.W.1    Mikhajlova, T.L.2    Stoinov, S.3    Stimac, D.4    Vucelic, B.5    Lonovics, J.6
  • 17
    • 73949092345 scopus 로고    scopus 로고
    • Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
    • Reinisch W., de Villiers W., Bene L., Simon L., Racz I., Katz S., et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010, 16:233-242.
    • (2010) Inflamm Bowel Dis , vol.16 , pp. 233-242
    • Reinisch, W.1    de Villiers, W.2    Bene, L.3    Simon, L.4    Racz, I.5    Katz, S.6
  • 18
    • 33746132472 scopus 로고    scopus 로고
    • A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease
    • Reinisch W., Hommes D.W., Van Assche G., Colombel J.F., Gendre J.P., Oldenburg B., et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006, 55:1138-1144.
    • (2006) Gut , vol.55 , pp. 1138-1144
    • Reinisch, W.1    Hommes, D.W.2    Van Assche, G.3    Colombel, J.F.4    Gendre, J.P.5    Oldenburg, B.6
  • 20
    • 53049091561 scopus 로고    scopus 로고
    • A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
    • Sandborn W.J., Feagan B.G., Fedorak R.N., Scherl E., Fleisher M.R., Katz S., et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008, 135:1130-1141.
    • (2008) Gastroenterology , vol.135 , pp. 1130-1141
    • Sandborn, W.J.1    Feagan, B.G.2    Fedorak, R.N.3    Scherl, E.4    Fleisher, M.R.5    Katz, S.6
  • 21
    • 84871701834 scopus 로고    scopus 로고
    • Ustekinumab induction and maintenance therapy in refractory Crohn's disease
    • Sandborn W.J., Gasink C., Gao L.L., Blank M.A., Johanns J., Guzzo C., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012, 367:1519-1528.
    • (2012) N Engl J Med , vol.367 , pp. 1519-1528
    • Sandborn, W.J.1    Gasink, C.2    Gao, L.L.3    Blank, M.A.4    Johanns, J.5    Guzzo, C.6
  • 22
    • 67650224449 scopus 로고    scopus 로고
    • Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease
    • Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009, 58:1152-1167.
    • (2009) Gut , vol.58 , pp. 1152-1167
    • Brand, S.1
  • 23
    • 84860996207 scopus 로고    scopus 로고
    • Th17-related cytokines in inflammatory bowel diseases: friends or foes?
    • Monteleone I., Sarra M., Pallone F., Monteleone G. Th17-related cytokines in inflammatory bowel diseases: friends or foes?. Curr Mol Med 2012, 12:592-597.
    • (2012) Curr Mol Med , vol.12 , pp. 592-597
    • Monteleone, I.1    Sarra, M.2    Pallone, F.3    Monteleone, G.4
  • 25
    • 84868680312 scopus 로고    scopus 로고
    • Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
    • Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012, 61:1693-1700.
    • (2012) Gut , vol.61 , pp. 1693-1700
    • Hueber, W.1    Sands, B.E.2    Lewitzky, S.3    Vandemeulebroecke, M.4    Reinisch, W.5    Higgins, P.D.6
  • 27
    • 36749038197 scopus 로고    scopus 로고
    • Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease
    • Kugathasan S., Saubermann L.J., Smith L., Kou D., Itoh J., Binion D.G., et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007, 56:1696-1705.
    • (2007) Gut , vol.56 , pp. 1696-1705
    • Kugathasan, S.1    Saubermann, L.J.2    Smith, L.3    Kou, D.4    Itoh, J.5    Binion, D.G.6
  • 28
    • 34247586091 scopus 로고    scopus 로고
    • Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis
    • Fichtner-Feigl S., Fuss I.J., Young C.A., Watanabe T., Geissler E.K., Schlitt H.J., et al. Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007, 178:5859-5870.
    • (2007) J Immunol , vol.178 , pp. 5859-5870
    • Fichtner-Feigl, S.1    Fuss, I.J.2    Young, C.A.3    Watanabe, T.4    Geissler, E.K.5    Schlitt, H.J.6
  • 29
    • 44949221585 scopus 로고    scopus 로고
    • An insight into molecular mechanisms of human T helper cell differentiation
    • Rautajoki K.J., Kylaniemi M.K., Raghav S.K., Rao K., Lahesmaa R. An insight into molecular mechanisms of human T helper cell differentiation. Ann Med 2008, 40:322-335.
    • (2008) Ann Med , vol.40 , pp. 322-335
    • Rautajoki, K.J.1    Kylaniemi, M.K.2    Raghav, S.K.3    Rao, K.4    Lahesmaa, R.5
  • 30
    • 15744390341 scopus 로고    scopus 로고
    • Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease
    • Monteleone G., Monteleone I., Fina D., Vavassori P., Del Vecchio Blanco G., Caruso R., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005, 128:687-694.
    • (2005) Gastroenterology , vol.128 , pp. 687-694
    • Monteleone, G.1    Monteleone, I.2    Fina, D.3    Vavassori, P.4    Del Vecchio Blanco, G.5    Caruso, R.6
  • 31
  • 32
    • 23244455992 scopus 로고    scopus 로고
    • Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution
    • Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129:550-564.
    • (2005) Gastroenterology , vol.129 , pp. 550-564
    • Heller, F.1    Florian, P.2    Bojarski, C.3    Richter, J.4    Christ, M.5    Hillenbrand, B.6
  • 33
    • 54349118972 scopus 로고    scopus 로고
    • The role of IL-13 and NK T cells in experimental and human ulcerative colitis
    • Fuss I.J., Strober W. The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol 2008, 1(1 Suppl.):S31-S33.
    • (2008) Mucosal Immunol , vol.1 , Issue.1 SUPPL.
    • Fuss, I.J.1    Strober, W.2
  • 34
    • 0036850908 scopus 로고    scopus 로고
    • Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells
    • Heller F., Fuss I.J., Nieuwenhuis E.E., Blumberg R.S., Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002, 17:629-638.
    • (2002) Immunity , vol.17 , pp. 629-638
    • Heller, F.1    Fuss, I.J.2    Nieuwenhuis, E.E.3    Blumberg, R.S.4    Strober, W.5
  • 35
    • 79952532799 scopus 로고    scopus 로고
    • Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production
    • Mannon P.J., Hornung R.L., Yang Z., Yi C., Groden C., Friend J., et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut 2011, 60:449-455.
    • (2011) Gut , vol.60 , pp. 449-455
    • Mannon, P.J.1    Hornung, R.L.2    Yang, Z.3    Yi, C.4    Groden, C.5    Friend, J.6
  • 36
    • 84865013186 scopus 로고    scopus 로고
    • Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis
    • Sandborn W.J., Ghosh S., Panes J., Vranic I., Su C., Rousell S., et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012, 367:616-624.
    • (2012) N Engl J Med , vol.367 , pp. 616-624
    • Sandborn, W.J.1    Ghosh, S.2    Panes, J.3    Vranic, I.4    Su, C.5    Rousell, S.6
  • 37
  • 38
    • 69949133374 scopus 로고    scopus 로고
    • Chemokines as novel therapeutic targets for inflammatory bowel disease
    • Nishimura M., Kuboi Y., Muramoto K., Kawano T., Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann N Y Acad Sci 2009, 1173:350-356.
    • (2009) Ann N Y Acad Sci , vol.1173 , pp. 350-356
    • Nishimura, M.1    Kuboi, Y.2    Muramoto, K.3    Kawano, T.4    Imai, T.5
  • 39
    • 33750716541 scopus 로고    scopus 로고
    • Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis
    • Rivera-Nieves J., Ho J., Bamias G., Ivashkina N., Ley K., Oppermann M., et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006, 131:1518-1529.
    • (2006) Gastroenterology , vol.131 , pp. 1518-1529
    • Rivera-Nieves, J.1    Ho, J.2    Bamias, G.3    Ivashkina, N.4    Ley, K.5    Oppermann, M.6
  • 40
    • 77954126169 scopus 로고    scopus 로고
    • GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease
    • Eksteen B., Adams D.H. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. Drugs 2010, 13:472-781.
    • (2010) Drugs , vol.13 , pp. 472-781
    • Eksteen, B.1    Adams, D.H.2
  • 41
    • 79955396012 scopus 로고    scopus 로고
    • The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice
    • Wermers J.D., McNamee E.N., Wurbel M.A., Jedlicka P., Rivera-Nieves J. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology 2011, 140:1526-1535.
    • (2011) Gastroenterology , vol.140 , pp. 1526-1535
    • Wermers, J.D.1    McNamee, E.N.2    Wurbel, M.A.3    Jedlicka, P.4    Rivera-Nieves, J.5
  • 42
    • 0034903450 scopus 로고    scopus 로고
    • A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease
    • Gordon F.H., Lai C.W., Hamilton M.I., Allison M.C., Srivastava E.D., Fouweather M.G., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001, 121:268-274.
    • (2001) Gastroenterology , vol.121 , pp. 268-274
    • Gordon, F.H.1    Lai, C.W.2    Hamilton, M.I.3    Allison, M.C.4    Srivastava, E.D.5    Fouweather, M.G.6
  • 44
    • 20444469332 scopus 로고    scopus 로고
    • Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin
    • Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Pare P., McDonald J.W., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
    • (2005) N Engl J Med , vol.352 , pp. 2499-2507
    • Feagan, B.G.1    Greenberg, G.R.2    Wild, G.3    Fedorak, R.N.4    Pare, P.5    McDonald, J.W.6
  • 45
    • 79953801792 scopus 로고    scopus 로고
    • Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis
    • Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
    • (2011) Am J Gastroenterol , vol.106 , pp. 644-659
    • Ford, A.C.1    Sandborn, W.J.2    Khan, K.J.3    Hanauer, S.B.4    Talley, N.J.5    Moayyedi, P.6
  • 46
    • 0036263171 scopus 로고    scopus 로고
    • P53 negatively regulates intestinal immunity by delaying mucosal T cell cycling
    • Sturm A., Itoh J., Jacobberger J.W., Fiocchi C. p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest 2002, 109:1481-1492.
    • (2002) J Clin Invest , vol.109 , pp. 1481-1492
    • Sturm, A.1    Itoh, J.2    Jacobberger, J.W.3    Fiocchi, C.4
  • 47
    • 33847000579 scopus 로고    scopus 로고
    • Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications
    • Mudter J., Neurath M.F. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007, 56:293-303.
    • (2007) Gut , vol.56 , pp. 293-303
    • Mudter, J.1    Neurath, M.F.2
  • 48
    • 79957673711 scopus 로고    scopus 로고
    • IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer
    • Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011, 22:83-89.
    • (2011) Cytokine Growth Factor Rev , vol.22 , pp. 83-89
    • Neurath, M.F.1    Finotto, S.2
  • 49
    • 0036151047 scopus 로고    scopus 로고
    • Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
    • ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
    • (2002) Gut , vol.50 , pp. 206-211
    • ten Hove, T.1    van Montfrans, C.2    Peppelenbosch, M.P.3    van Deventer, S.J.4
  • 50
    • 0030954732 scopus 로고    scopus 로고
    • A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group
    • Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
    • (1997) N Engl J Med , vol.337 , pp. 1029-1035
    • Targan, S.R.1    Hanauer, S.B.2    van Deventer, S.J.3    Mayer, L.4    Present, D.H.5    Braakman, T.6
  • 51
    • 32044451548 scopus 로고    scopus 로고
    • Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
    • Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
    • (2006) Gastroenterology , vol.130 , pp. 323-333
    • Hanauer, S.B.1    Sandborn, W.J.2    Rutgeerts, P.3    Fedorak, R.N.4    Lukas, M.5    MacIntosh, D.6
  • 52
    • 0034754477 scopus 로고    scopus 로고
    • Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial
    • Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
    • (2001) Gastroenterology , vol.121 , pp. 1088-1094
    • Sandborn, W.J.1    Hanauer, S.B.2    Katz, S.3    Safdi, M.4    Wolf, D.G.5    Baerg, R.D.6
  • 55
    • 19344374130 scopus 로고    scopus 로고
    • Smad7 in TGF-beta-mediated negative regulation of gut inflammation
    • Monteleone G., Pallone F., MacDonald T.T. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol 2004, 25:513-517.
    • (2004) Trends Immunol , vol.25 , pp. 513-517
    • Monteleone, G.1    Pallone, F.2    MacDonald, T.T.3
  • 57
    • 33845647693 scopus 로고    scopus 로고
    • Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis
    • Boirivant M., Pallone F., Di Giacinto C., Fina D., Monteleone I., Marinaro M., et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 2006, 131:1786-1798.
    • (2006) Gastroenterology , vol.131 , pp. 1786-1798
    • Boirivant, M.1    Pallone, F.2    Di Giacinto, C.3    Fina, D.4    Monteleone, I.5    Marinaro, M.6
  • 58
    • 84859439270 scopus 로고    scopus 로고
    • Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease
    • Monteleone G., Fantini M.C., Onali S., Zorzi F., Sancesario G., Bernardini S., et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012, 20:870-876.
    • (2012) Mol Ther , vol.20 , pp. 870-876
    • Monteleone, G.1    Fantini, M.C.2    Onali, S.3    Zorzi, F.4    Sancesario, G.5    Bernardini, S.6
  • 59
    • 84878568056 scopus 로고    scopus 로고
    • A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease
    • Zorzi F., Calabrese E., Monteleone I., Fantini M., Onali S., Biancone L., et al. A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther 2012, 36:850-857.
    • (2012) Aliment Pharmacol Ther , vol.36 , pp. 850-857
    • Zorzi, F.1    Calabrese, E.2    Monteleone, I.3    Fantini, M.4    Onali, S.5    Biancone, L.6
  • 60
    • 0027521572 scopus 로고
    • Interleukin-10-deficient mice develop chronic enterocolitis
    • Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
    • (1993) Cell , vol.75 , pp. 263-274
    • Kuhn, R.1    Lohler, J.2    Rennick, D.3    Rajewsky, K.4    Muller, W.5
  • 61
    • 70949087383 scopus 로고    scopus 로고
    • Inflammatory bowel disease and mutations affecting the interleukin-10 receptor
    • Glocker E.O., Kotlarz D., Boztug K., Gertz E.M., Schaffer A.A., Noyan F., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009, 361:2033-2045.
    • (2009) N Engl J Med , vol.361 , pp. 2033-2045
    • Glocker, E.O.1    Kotlarz, D.2    Boztug, K.3    Gertz, E.M.4    Schaffer, A.A.5    Noyan, F.6
  • 62
    • 84864206050 scopus 로고    scopus 로고
    • Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy
    • Kotlarz D., Beier R., Murugan D., Diestelhorst J., Jensen O., Boztug K., et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012, 143:347-355.
    • (2012) Gastroenterology , vol.143 , pp. 347-355
    • Kotlarz, D.1    Beier, R.2    Murugan, D.3    Diestelhorst, J.4    Jensen, O.5    Boztug, K.6
  • 63
    • 0034463305 scopus 로고    scopus 로고
    • Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group
    • Fedorak R.N., Gangl A., Elson C.O., Rutgeerts P., Schreiber S., Wild G., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000, 119:1473-1482.
    • (2000) Gastroenterology , vol.119 , pp. 1473-1482
    • Fedorak, R.N.1    Gangl, A.2    Elson, C.O.3    Rutgeerts, P.4    Schreiber, S.5    Wild, G.6
  • 64
    • 66149156478 scopus 로고    scopus 로고
    • Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut
    • Caruso R., Sarra M., Stolfi C., Rizzo A., Fina D., Fantini M.C., et al. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 2009, 136:2270-2279.
    • (2009) Gastroenterology , vol.136 , pp. 2270-2279
    • Caruso, R.1    Sarra, M.2    Stolfi, C.3    Rizzo, A.4    Fina, D.5    Fantini, M.C.6
  • 65
    • 18244387204 scopus 로고    scopus 로고
    • Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells
    • Rimoldi M., Chieppa M., Salucci V., Avogadri F., Sonzogni A., Sampietro G.M., et al. Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol 2005, 6:507-514.
    • (2005) Nat Immunol , vol.6 , pp. 507-514
    • Rimoldi, M.1    Chieppa, M.2    Salucci, V.3    Avogadri, F.4    Sonzogni, A.5    Sampietro, G.M.6
  • 66
    • 38849141814 scopus 로고    scopus 로고
    • IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis
    • Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118:534-544.
    • (2008) J Clin Invest , vol.118 , pp. 534-544
    • Sugimoto, K.1    Ogawa, A.2    Mizoguchi, E.3    Shimomura, Y.4    Andoh, A.5    Bhan, A.K.6
  • 67
    • 79959918506 scopus 로고    scopus 로고
    • Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract
    • Monteleone I., Rizzo A., Sarra M., Sica G., Sileri P., Biancone L., et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011, 141:237-248.
    • (2011) Gastroenterology , vol.141 , pp. 237-248
    • Monteleone, I.1    Rizzo, A.2    Sarra, M.3    Sica, G.4    Sileri, P.5    Biancone, L.6
  • 68
    • 84857657607 scopus 로고    scopus 로고
    • Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies
    • Bogdanos D.P., Rigopoulou E.I., Smyk D.S., Roggenbuck D., Reinhold D., Forbes A., et al. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmun Rev 2011, 11:143-148.
    • (2011) Autoimmun Rev , vol.11 , pp. 143-148
    • Bogdanos, D.P.1    Rigopoulou, E.I.2    Smyk, D.S.3    Roggenbuck, D.4    Reinhold, D.5    Forbes, A.6
  • 69
    • 3342988481 scopus 로고    scopus 로고
    • Inflammatory bowel disease: the role of environmental factors
    • Danese S., Sans M., Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004, 3:394-400.
    • (2004) Autoimmun Rev , vol.3 , pp. 394-400
    • Danese, S.1    Sans, M.2    Fiocchi, C.3
  • 70
    • 77649233106 scopus 로고    scopus 로고
    • The geoepidemiology of autoimmune intestinal diseases
    • Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010, 9:A372-A378.
    • (2010) Autoimmun Rev , vol.9
    • Logan, I.1    Bowlus, C.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.